These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7339819)

  • 1. Basis for lack of drug susceptibility of atypical mycobacteria.
    David HL
    Rev Infect Dis; 1981; 3(5):878-84. PubMed ID: 7339819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of antibiotic resistance in Mycobacterium intracellulare.
    Mizuguchi Y; Udou T; Yamada T
    Microbiol Immunol; 1983; 27(5):425-31. PubMed ID: 6312275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of mycobacteria, especially of Mycobacterium intracellulare, to 5-fluorouracil and pattern of development of resistance of Mycobacterium tuberculosis to the drug.
    Tsukamura M
    Microbiol Immunol; 1979; 23(5):427-9. PubMed ID: 116112
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
    Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
    Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycobacterial plasmids: screening and possible relationship to antibiotic resistance in Mycobacterium avium/Mycobacterium intracellulare.
    Franzblau SG; Takeda T; Nakamura M
    Microbiol Immunol; 1986; 30(9):903-7. PubMed ID: 3540539
    [No Abstract]   [Full Text] [Related]  

  • 6. A drug sensitivity test strategy for atypical mycobacteria.
    Hejný J
    Tubercle; 1982 Mar; 63(1):63-9. PubMed ID: 7082424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for determining the antimicrobial susceptibility of mycobacteria.
    Alcaide F; Esteban J; González-Martin J; Palacios JJ
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):529-535. PubMed ID: 27236235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility to antibiotics and sulfonamides of atypical mycobacteria isolated in South America.
    de Kantor IN; Barrera L; di Lonardo M
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Oct; 260(2):247-53. PubMed ID: 4082825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in the bacteriology of tuberculosis (including drug resistance and atypical Mycobacteria).
    Laidlaw M
    Scott Med J; 1978 Apr; 23(2):181. PubMed ID: 644301
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs.
    Marinis E; Legakis NJ
    J Antimicrob Chemother; 1985 Oct; 16(4):527-30. PubMed ID: 2933382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug susceptibility testing of nontuberculous mycobacteria.
    van Ingen J; Kuijper EJ
    Future Microbiol; 2014; 9(9):1095-110. PubMed ID: 25340838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Mycobacterium fortuitum to cefoxitin.
    Cynamon MH; Patapow A
    Antimicrob Agents Chemother; 1981 Jan; 19(1):205-7. PubMed ID: 7247358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin).
    Tsukamura M
    Microbiol Immunol; 1986; 30(9):931-3. PubMed ID: 3467156
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro susceptibility of atypical mycobacteria to cephalosporins.
    Garcia-Rodriguez JA; Martin-Luengo F
    Tubercle; 1980 Mar; 61(1):39-40. PubMed ID: 7368324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of some quinoline derivatives against Mycobacterium fortuitum.
    Valero-Guillén PL; Martín-Luengo F; Quintanilla I
    J Antimicrob Chemother; 1985 Feb; 15(2):254-5. PubMed ID: 3980314
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo susceptibility of atypical mycobacteria to various drugs.
    Kuze F; Kurasawa T; Bando K; Lee Y; Maekawa N
    Rev Infect Dis; 1981; 3(5):885-97. PubMed ID: 7339820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria.
    Li G; Pang H; Guo Q; Huang M; Tan Y; Li C; Wei J; Xia Y; Jiang Y; Zhao X; Liu H; Zhao LL; Liu Z; Xu D; Wan K
    Int J Antimicrob Agents; 2017 Mar; 49(3):364-374. PubMed ID: 28131606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of infections caused by 'atypical' mycobacteria.
    Grange JM
    J Antimicrob Chemother; 1984 Apr; 13(4):308-10. PubMed ID: 6725182
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro susceptibility of mycobacterium fortuitum and mycobacterium chelonei to cefoxitin.
    Casal M; Rodríguez F
    Tubercle; 1982 Jun; 63(2):125-7. PubMed ID: 7179478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.